No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.

Wang, Jenny Z; Le, Stephanie; Alexanian, Claire; Boddu, Sucharita; Merleev, Alexander; Marusina, Alina; Maverakis, Emanual

Wang, Jenny Z; Le, Stephanie; Alexanian, Claire; Boddu, Sucharita; Merleev, Alexander; Marusina, Alina; Maverakis, Emanual.

Afiliação

Wang JZ; Albert Einstein College of Medicine, Bronx, NY, USA.
Le S; Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA.
Alexanian C; Georgetown University School of Medicine, Washington, DC, USA.
Boddu S; Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA.
Merleev A; Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA.
Marusina A; Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA.
Maverakis E; Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA. emaverakis@ucdavis.edu.

World J Mens Health ; 37(3): 313-321, 2019 Sep.

Article em En | MEDLINE | ID: mdl-30350485

Palavras-chave

Melanoma; Phosphodiesterase 5 inhibitors; Sildenafil citrate; Tadalafil; Vardenafil dihydrochloride

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Systematic_reviews Idioma: En Revista: World J Mens Health Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google